Melatonin (Alpha Science Laboratories)
Natural health product licensed in Canada
- Licence holder
- Omega Alpha Pharmaceuticals Inc.
- NPN or DIN-HM
- 80076194
- Status
- Active licence
- Licence date
- 17 March 2017
- Revision date
- Not provided
- Form
- Comprimé
- Route of administration
- Sublinguale
- Application type
- Officinale
Oral dose analysis does not apply without an established exclusively oral route.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source |
|---|---|
| N-acétyl-5-méthoxytryptamine Source : Mélatonine | 3 milligramme |
Non-medicinal ingredients
D-Fructose, Cellulose microcristalline, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | minimum: 1 Comprimé ; maximum: 2 Comprimé | 1 Tous les jours |
Uses authorised in Canada
Helps increase the total sleep time (aspect of sleep quality) in people suffering from sleep restriction or altered sleep schedule, e.g. shift-work and jet lag.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
If you are pregnant or breastfeeding, do not use this product.
- Effets indésirables connus
Mild gastrointestinal symptoms (nausea, vomiting, or cramping) have been known to occur in which case, discontinue use. Rare allergic reactions have been known to occur in which case, discontinue use.
- Précautions et mises en garde
Consumption with alcohol, other medications or natural health products with sedative properties is not recommended. If you are taking one of the following medications, consult a health care practitioner prior to use: anticoagulant, anticonvulsant, blood pressure medications, immunosuppressive medications, sedative, hypnotic or psychotropic medications, or steroids. If you have one of the following conditions, consult a health care practitioner prior to use: asthma, cardiovascular disease, chronic kidney disease, depression, diabetes or hypoglycaemia, hormonal disorder, immune system disease, liver disease, migraine, or seizure disorders. If symptoms persist continuously for more than 4 weeks (chronic insomnia), consult your health care practitioner.
Source
Official Health Canada record, licence 80076194
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.